You are here

TX-004HR

TherapeuticsMD shares drop 7% on new FDA review timeline for its drug

TherapeuticsMD shares drop 7% on new FDA review timeline for its drug

Marketwatch

Flag link:

FDA agrees to review TherapeuticsMD drug, dropping safety demands

FDA agrees to review TherapeuticsMD drug, dropping safety demands

BioPharma Dive

Flag link:

Nixed by the FDA, TherapeuticsMD is now planning a long-shot bid to reverse the decision

Nixed by the FDA, TherapeuticsMD is now planning a long-shot bid to reverse the decision

Endpoints

Flag link:

5 Key BioPharma Movers That Cannot Be Ignored

5 Key BioPharma Movers That Cannot Be Ignored

24/7 Wall St

Idera Pharmaceuticals

Cara Therapeutics

Flag link:

Successful Vaginal Pain Drug Trial Sends TherapeuticsMD Soaring

Successful Vaginal Pain Drug Trial Sends TherapeuticsMD Soaring

Bloomberg

clinical trials

Flag link: